Literature DB >> 24338608

Von Willebrand factor: form for function.

Andrew Yee1, Colin A Kretz1.   

Abstract

The mechanisms by which von Willebrand factor (VWF) achieves hemostasis lie in its structure. Whereas low-molecular-weight forms have diminished hemostatic potential, ultralarge VWF (ULVWF) in excess is potentially thrombogenic. VWF comprises many subunits, which themselves comprise many repeated domains/assemblies possessing characteristic function(s). Organization of these domains/assemblies into a multimeric structure effectively links and replicates these functions. Each domain/assembly influences the synthesis, assembly, secretion, or hemostatic potential of plasma VWF. The C-terminal CT/CK domain mediates dimerization of VWF subunits in the endoplasmic reticulum, while the N-terminal D1D2 assemblies catalyzes disulfide binding between juxtaposed D3 assemblies in the trans-Golgi, creating multimers. The pH-sensitive domains (A2-CT/CK) allow ULVWF multimers to orderly pack into tubules that unravel upon secretion into the circulation. Hemodynamic forces regulate the conformation of the A2 domain and thus, its accessibility to proteolytic enzyme(s) that regulate VWF's hemostatic potential. Binding to the VWF D'D3 assemblies stabilizes coagulation factor VIII. The VWF A1 and A3 domains facilitate platelet capture onto exposed collagen(s) at sites of vascular injury. Our deeper understanding of VWF provided through the recent growth in VWF structure-function studies may potentially guide novel therapeutics for clotting or bleeding disorders. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338608     DOI: 10.1055/s-0033-1363155

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  22 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

3.  Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Authors:  Andrew Yee; Austin N Oleskie; Anne M Dosey; Colin A Kretz; Robert D Gildersleeve; Somnath Dutta; Min Su; David Ginsburg; Georgios Skiniotis
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 4.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

Review 5.  von Willebrand factor, Jedi knight of the bloodstream.

Authors:  Timothy A Springer
Journal:  Blood       Date:  2014-06-13       Impact factor: 22.113

Review 6.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

7.  Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13.

Authors:  Colin A Kretz; Manhong Dai; Onuralp Soylemez; Andrew Yee; Karl C Desch; David Siemieniak; Kärt Tomberg; Fyodor A Kondrashov; Fan Meng; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

8.  Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.

Authors:  Omid Seidizadeh; Luciano Baronciani; Maria Teresa Pagliari; Giovanna Cozzi; Paola Colpani; Andrea Cairo; Simona Maria Siboni; Eugenia Biguzzi; Flora Peyvandi
Journal:  Blood Adv       Date:  2022-07-12

9.  Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies.

Authors:  Nancy A Turner; Sarah E Sartain; Shiu-Ki Hui; Joel L Moake
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

10.  Phage display broadly identifies inhibitor-reactive regions in von Willebrand factor.

Authors:  Andrew Yee; Manhong Dai; Stacy E Croteau; Jordan A Shavit; Steven W Pipe; David Siemieniak; Fan Meng; David Ginsburg
Journal:  J Thromb Haemost       Date:  2021-07-28       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.